Business Context and Reporting Period
The filing is Aileron Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. The request metadata identifies Rein Therapeutics, Inc.; investors should verify the issuer identity because the filing itself names Aileron Therapeutics, Inc. and trades under Nasdaq symbol ALRN.
Aileron is a clinical-stage oncology company. In February 2023, it terminated further development of ALRN-6924 after trial data showed severe neutropenia and alopecia, reduced its workforce from nine to three employees, and began evaluating strategic alternatives, including an acquisition, merger, business combination, asset sale, dissolution, or other transaction.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 in 2023 and 2022 | $0 in 2023 and 2022 |
| Research and development expense | $0.02 million vs. $4.24 million | $2.02 million vs. $15.57 million |
| General and administrative expense | $1.96 million vs. $2.24 million | $6.03 million vs. $7.38 million |
| Restructuring and other expense | $0.01 million vs. $0 | $0.94 million vs. $0 |
| Net loss | $1.83 million, or $0.40 per share, vs. $6.37 million, or $1.40 per share | $8.39 million, or $1.85 per share, vs. $22.78 million, or $5.02 per share |
| Net cash used in operating activities | Not separately reported | $9.42 million vs. $20.46 million |
At September 30, 2023, cash and cash equivalents were $12.07 million, compared with $5.19 million at December 31, 2022. The company held no investments at September 30, 2023, compared with $16.05 million at year-end 2022. Total assets were $12.82 million and total liabilities were $1.62 million. Stockholders’ equity was $11.20 million, and accumulated deficit was $281.18 million.
Cash, cash equivalents, and restricted cash increased by $6.88 million during the first nine months, primarily because $16.29 million of investment maturities and sales exceeded $9.42 million of operating cash use. No financing cash was raised during the period. The company had no debt reported in the filing.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined 87% for the nine-month period, primarily because of completed or terminated clinical studies, lower manufacturing costs, and reduced personnel costs.
- General and administrative expense declined 18% for the nine-month period, primarily due to lower headcount costs.
- Net loss improved by $14.39 million for the nine-month period, although the company remained unprofitable and generated no revenue.
- The company incurred $0.94 million of one-time workforce-reduction costs; $0.93 million had been paid by September 30, with the remaining $0.01 million expected to be paid in the fourth quarter of 2023.
- The company’s former office sublease expired March 31, 2023, and operations are now conducted virtually.
- Outstanding common shares remained 4,541,167. At September 30, 2023, the company also had 646,759 warrants and 468,617 stock options outstanding, which were excluded from diluted loss-per-share calculations because they were anti-dilutive.
Guidance, Outlook, Risks, and Unusual Items
Management expects operating expenses, particularly research and development expense, to continue declining in the fourth quarter of 2023 following the program termination and workforce reduction. Management stated that cash and cash equivalents of approximately $12.1 million were expected to fund operating expenses for at least twelve months based on the current operating plan, subject to the outcome and costs of the strategic review.
Despite that statement, the company concluded that substantial doubt exists about its ability to continue as a going concern for twelve months after issuance of the financial statements. The company needs substantial additional funding, and there is no assurance that a strategic transaction will be completed. If no transaction is achieved, the board may pursue dissolution and liquidation or seek bankruptcy protection. The filing states that stockholders could receive little or nothing in a liquidation or bankruptcy.
The company has no product candidates under development and does not expect product revenue. Potential future financing could involve equity dilution, convertible securities, debt, liens, or restrictive covenants. The company also stated that its equity line with Lincoln Park Capital was unavailable because its Nasdaq closing price was below the applicable $6.00 floor price, and it did not expect to access that facility in the foreseeable future.
Other notable items include $0.32 million of interest income for the nine-month period, $0.27 million of other income, $0.92 million of stock-based compensation expense, and a reduction in annual Harvard/Dana-Farber license maintenance fees from $0.11 million to $0.035 million. No material legal proceedings were reported. Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Review the going-concern disclosure and determine whether the strategic review produces a transaction, liquidation, or bankruptcy filing.
- Reconcile the $12.07 million cash balance with ongoing operating cash burn and expected costs of the strategic process.
- Monitor Nasdaq listing compliance and the company’s ability to obtain additional financing, given the unavailable equity line and lack of current product revenue.
- Assess potential recoveries for common stockholders under any merger, asset sale, dissolution, or bankruptcy scenario.
- Review the status and expiration of the 646,759 common warrants, which had a $40.00 exercise price and were scheduled to expire in April 2024.